TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04178369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proximal And Distal Tibiofibular Joint Manipulations
Description: For PTFJ, the experimental intervention will be based on previously published methods. Physiotherapist will make contact with the fibular head, extending to the popliteal fossa. The associated soft tissue will be pulled in a lateral direction until the metacarpophalangeal joint will be firmly stabilized behind the fibular head.~For DTFJ, the experimental intervention will be conducted according to previously published methods. Physiotherapist will grasp and stabilize the distal tibia with one hand and grasp the distal fibula between the finger and thenar eminence of the other hand. The fibula will be translated posteriorly until the restrictive barrier (end range) will be engaged. Then a high-velocity, low-amplitude thrust will be applied through the fibula in a posterior-superior direction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bobath Treatment
Description: All participants will be given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept for 5 days a week, 45 minutes each. The techniques will be applied by a physiotherapist who is specialized in Bobath concept. 35 different techniques will be used to improve the selective control and weight transfer of the pelvis in sitting, standing and supine/side lying positions. Moreover, soft tissue mobilization will be also used to relieve tension and loosen stiff tissues to provide biomechanical alignment and reduce pain.
Study: NCT02562690

Intervention type: OTHER
Intervention: Thrombin generation assays, TEG and GTT
Description: Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
Study: NCT01973530

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: femoral nerve block
Description: Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
Study: NCT04152980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
Study: NCT03012529

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riboflavin Placebo
Description: A placebo capsule will be administered daily to match frequency and duration of rifampin interventional drug. For the purpose of mimicking urine discoloration when taking rifampin, riboflavin will be added to the placebo to produce a urine discoloration effect.
Study: NCT03986697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biktarvy
Description: Fixed dose combination preparation containing bictegravir, tenofovir alafenamide and emtricitabine
Study: NCT02625558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given three times a day
Study: NCT03635320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TFNA
Description: intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFNA-II
Description: intramedullary nail ' Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation
Study: NCT05911152

Intervention type: PROCEDURE
Intervention: Intracorporeal anastomosis
Description: Surgeons perform totally laparoscopic intracorporeal digestive reconstruction after specimen resection
Study: NCT00221299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: One 35mg tab of risedronate/placebo taken once a week for one year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: One 35mg tab of risedronate/placebo taken once a week for one year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: One 35mg tab of risedronate/placebo taken once a week for one year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid Hormone
Description: This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid Hormone
Description: This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid Hormone
Description: This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.
Study: NCT03749187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP Inhibitor BGB-290
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP Inhibitor BGB-290
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT06562621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ON-01
Description: ON-01 consists of a yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5-FC) to the anticancer drug 5-FU in cells that have been infected by ON-01.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONF
Description: ONF is an extended-release formulation of flucytosine.
Study: NCT01609257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent Vaccine
Description: 2 doses IM 28 days apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Comparator
Description: 2 doses IM 28 days apart
Study: NCT04002024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizer with active ingredients
Description: Moisturizer with active ingredients: 1 fingertip unit to cover one side of the face twice a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizer with active ingredients
Description: Moisturizer with active ingredients: 1 fingertip unit to cover one side of the face twice a day
Study: NCT04761354

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy
Study: NCT04002024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo: 1 fingertip unit to cover one side of the face twice a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo: 1 fingertip unit to cover one side of the face twice a day
Study: NCT04393844

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: turbo-ject PICC set
Description: The turbo-ject PICC set, which will be used in this study, is the set for peripherally inserted central catheterization. In this study, we will see the difference according to the presence or absence of the hydrophilic coated stiffening obturator included in this turbo-ject PICC set.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: turbo-ject PICC set
Description: The turbo-ject PICC set, which will be used in this study, is the set for peripherally inserted central catheterization. In this study, we will see the difference according to the presence or absence of the hydrophilic coated stiffening obturator included in this turbo-ject PICC set.
Study: NCT04332185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vestibular socket therapy
Description: (VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
Study: NCT01590966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Cimzia®
Description: Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoscintigraphy with radiolabeled Cimzia®.
Description: All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
Study: NCT04240847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin incision
Description: Skin incision on medial or lateral to tibial tubercle
Study: NCT01964456

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Joint perception task
Study: NCT03169283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal with B glucan
Description: A cereal high in viscous dietary fiber B glucan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal without B glucan
Description: Cereal without B glucan
Study: NCT03560440

Intervention type: OTHER
Intervention: Plasma exposure vancomycin
Description: Investigation of plasma exposure of vancomycin.
Study: NCT04240847

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin incision
Description: Skin incision on medial or lateral to tibial tubercle
Study: NCT03607695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait training
Description: Walking on a treadmill and receiving audio cues to improve gait
Study: NCT02245373

Intervention type: DRUG
Intervention: Antidepressants

Intervention type: OTHER
Intervention: Active Monitoring
Study: NCT04627753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, lenalidomide
Description: Maintenance for 2 years
Study: NCT01124474

Intervention type: OTHER
Group type: OTHER
Intervention: goal directed therapy
Description: Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV\>12%.
Study: NCT04064710

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vertebral Body Augmentation
Description: Use allograft tissue in patients with one or two level, thoracic or lumbar T6-L5, vertebral compression fractures.

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual Surgical Instruments
Description: Lenoss Medical manual surgical access and cavity creation instruments will be used when implanting the allograft tissue.
Study: NCT04010422

Intervention type: DIAGNOSTIC_TEST
Intervention: no intervention
Description: no intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: no intervention
Description: no intervention
Study: NCT02285010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.~Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
Study: NCT01274897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis MenACWY-CRM
Description: All subjects had blood drawn at Day 1 and Day 29.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: All subjects had blood drawn at Day 1 and Day 29.
Study: NCT03388970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K 1
Description: Research group use Vitamin K1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Placebo group use normal saline
Study: NCT00853905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triesence
Description: At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: balanced salt solution BSS
Description: At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure.
Study: NCT04079777

Intervention type: DRUG
Intervention: Clinical treatment
Description: Liquid Resuscitation, Anti-infection

Intervention type: DRUG
Intervention: Clinical treatment
Description: Liquid Resuscitation, Anti-infection
Study: NCT05828940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: oral tablet, over-encapsulated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, over-encapuslated
Study: NCT01088412

Intervention type: DRUG
Intervention: Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)
Description: Dose, frequency and duration at discretion of attending physician.
Study: NCT04222621

Intervention type: OTHER
Intervention: Pregnant women without intervention
Description: Pregnant women with those exposures of interest determined in specific research based on the registry
Study: NCT02024581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% East Indian sandalwood oil cream
Description: A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
Study: NCT01240018

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Parallel, randomized, controlled 2 arms study.
Study: NCT01422447

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular intervention
Description: the subjects in the control group live in the used model
Study: NCT01240018

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Parallel, randomized, controlled 2 arms study.
Study: NCT02786537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF/LDV (sofosbuvir/ledipasvir)
Description: Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF/LDV (sofosbuvir/ledipasvir)
Description: Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
Study: NCT01422447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: community intervention
Description: in addition to regular intervention, those subjects in the intervention group will be given education intervention.
Study: NCT01964456

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint perception task

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Body Shape Questionnaire

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Shape Questionnaire

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Measure of the heart rate
Study: NCT01660243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalfurafine hydrochloride(MT-9938) 2.5μg
Description: 2.5 μg (2capsules) once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalfurafine hydrochloride(MT-9938) 5μg
Description: 5 μg (2capsules) once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalfurafine hydrochloride(MT-9938) 10μg
Description: 10 μg (2capsules) once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2capsules) once daily for 8 weeks
Study: NCT03521973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Sodium chloride

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Sodium chloride

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Sodium chloride
Study: NCT02127463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC-1101
Description: Topically, two times a day, morning and bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MC-1101 Vehicle
Description: Topically, two times a day; morning and bedtime
Study: NCT00951457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Study: NCT03541538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Global manipulation
Description: The therapist positioned himself at the head of the stretcher and with one hand supported the side of the participant's face. With the other hand supported the opposite face of the same and then performed contralateral rotation of the cervical and a slight traction to the tissue barrier to perform the manipulation impulse of high speed and short amplitude in rotation. The procedure was carried out bilaterally.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Especific manipulation
Description: The therapist positioned himself at the head of the stretcher and with one hand kept the middle phalange of the second finger laterally on the articular processes of the C6-7 vertebrae. With the contralateral hand he supported the opposing face of the participant by performing a tilt up to the C6-7 segment and contralateral rotation up to the tissue barrier to carry out the impulse quickly and short. The procedure was carried out bilaterally.
Study: NCT03415308

Intervention type: OTHER
Intervention: Focus Groups
Description: Investigators will use qualitative methods to gather data on the elements associated with the patient perception of implicit bias (e.g. communication, respect, patient-centeredness) to ensure that our selected outcomes reflect the breadth of patients' concerns.

Intervention type: OTHER
Intervention: Cognitive Interviews
Description: To gather insights from stakeholders regarding how to best refine the design of our existing implicit bias intervention to ensure that we have addressed potential facilitators and barriers to uptake, use, and sustainability

Intervention type: OTHER
Intervention: Pilot Testing of Implicit Bias Training
Description: Determine the feasibility of delivering the refined implicit bias reduction intervention and assessing patient centered outcomes by giving providers a refined implicit bias training.
Study: NCT02097160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D fortified yogurt and cheese products

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D fortified yogurt and cheese products

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group 1